NVS opens DDI trial of ENTA’s EDP-239 + Alisporvir in healthy volunteers: http://clinicaltrials.gov/ct2/show/NCT02173574 If the DDI trial proceeds without a hitch, NVS will follow with a phase-2b study of the drug combination in HCV patients. at which time ENTA will earn a $15M milestone payment from NVS. Related info: #msg-103400913. (H/t @lomu_j re trial opening.)